| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Date of report (Date of earliest event reported): November 13, 2026 |
| 16 Nov 2026 | 424B5 |
| 12 Nov 2026 | 424B5 |
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition; Other Events
- Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - |
| 12 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
- Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR procedures annually – |
| 23 Sep 2026 |
Form 4: Berman Michael, Director
Disposed of 30,625 Series J Warrant (right to buy) (Other Transaction) · Acquired 30,625 Series J Warrant (right to buy) (Other Transaction) · Disposed of 61,248 Series K Warrant (right to buy) (Other Transaction) · 1 more |
| 23 Sep 2026 |
Form 4: Roubin Gary S, Director
Disposed of 15,313 Series J Warrant (right to buy) (Other Transaction) · Acquired 15,313 Series J Warrant (right to buy) (Other Transaction) · Disposed of 30,624 Series K Warrant (right to buy) (Other Transaction) · 1 more |
| 23 Sep 2026 |
Form 4: Stuka Paul, Director
Disposed of 43,750 Series J Warrant (right to buy) (Other Transaction) · Acquired 43,750 Series J Warrant (right to buy) (Other Transaction) · Disposed of 87,500 Series K Warrant (right to buy) (Other Transaction) · 1 more |
| 21 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more
THIS SERIES J COMMON STOCK PURCHASE WARRANT AMENDMENT (this “Amendment”) is entered into as of September 21, 2026, by and between InspireMD, Inc., a Delaware corporation (the “Company”), and the holder identified on the signature page he... |
| 17 Aug 2026 |
8-K: Results of Operations and Financial Condition
- Company to host investor conference call today, August 17th, at 8:30am EDT - |
| 14 Aug 2026 | 10-Q |
| 29 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 23, 2026, InspireMD, Inc. (the “Company”) provided notice to Shane Gleason, the Company’s Chief Commercial Officer, that his position has been eliminated. His last day of employment with the Company will be July 31, 2026. |
| 23 Jul 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On July 17, 2026, InspireMD, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum b... |
| 02 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 26, 2026, Mr. Raymond W. Cohen, a Class III member of the board of directors (the “Board”) of InspireMD, Inc. (the “Company”), a member of the Audit Committee of the Board and a member of the Compensation Committee of the Board, ... |
| 11 Jun 2026 |
8-K: Regulation FD Disclosure
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures |
| 03 Jun 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
InspireMD, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify that: |
| 29 May 2026 |
Form 4: Stuka Paul, Director
Bought 20,000 shares ($17.5K) |
| 22 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 20, 2026, Mr. Paul Stuka notified InspireMD, Inc. (the “Company”) of his decision to not seek reelection as a Class I director of the Board of Directors of the Company (the “Board”) at the Company’s 2027 Annual Meeting of Stockhol... |
| 21 May 2026 |
Form 4: Gleason Shane Thomas, Chief Commercial Officer
Sold 3,858 shares ($10.5K) · Sold 2,476 shares ($6.46K) · Sold 3,660 shares ($9K) · 11 more |
| 15 May 2026 | SCHEDULE 13G/A |
Loading...